India Pharma Outlook Team | Friday, 20 November 2026
GMP rules could see targeted relaxations as the Union Health Ministry considers retaining certain exemptions for select drug categories.
The proposal covers manufacturers of disinfectants, medicinal gases and empty gelatin capsules, who have raised concerns over infrastructure and equipment requirements that may not suit their manufacturing processes.
The proposed changes aim to reduce unnecessary compliance costs without weakening drug quality and safety standards.
However, the government has not finalized the amendment yet and has invited industry stakeholders and other interested parties to submit their feedback during a 30-day public consultation period.
The proposed changes follow requests from manufacturers of disinfectants, medicinal gases and empty gelatin capsules, who approached regulatory authorities seeking exemptions from certain revised Schedule M requirements.
These companies argue that some infrastructure and equipment requirements do not match the nature of their products and manufacturing processes. Meeting these specifications could also increase their manufacturing and compliance costs.
The Drugs Technical Advisory Board (DTAB), during its 93rd meeting, recommended continuing the existing exemptions for plant space and equipment.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
The draft amendment seeks to retain existing exemptions from specific space and equipment requirements under the revised Schedule M norms. The proposal could offer manufacturers greater flexibility while keeping essential production standards intact.
It also aims to align GMP rules with the specific requirements of different drug manufacturing categories. However, the proposal retains regulatory oversight. Central and state licensing officials will have the discretion to modify Schedule M requirements and direct manufacturers to make necessary changes at their production facilities.
The next steps include:
The proposed amendment signals an effort to balance regulatory flexibility with manufacturing costs and product quality. Until the government finalizes the changes, existing regulatory requirements will continue to guide manufacturers.